


05-23-02 H4

0300

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)		Docket No. GA0118USC	
Applicant(s): Nicolette			
Serial No. 10/041,977	Postmark MAY 21 2002 Filing Date January 9, 2002	Examiner Unassigned	Group Art Unit 1627
Invention: A METHOD FOR IDENTIFYING CYTOTOXIC T-CELL EPITOPES			
<p>I hereby certify that the following correspondence:</p> <div style="border: 1px solid black; padding: 5px;"><p>A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 sheets); Statement Under 37 C.F.R. 1.821(e) (2 sheets); Paper Copy of Sequence Listing (10 sheets); and Return Postcard</p></div> <p style="text-align: center;">(Identify type of correspondence)</p> <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on</p> <p style="text-align: center;"><u>May 21, 2002</u> (Date)</p> <div style="text-align: right; margin-top: 20px;"><p><u>TARYN ANTALEK</u> (Typed or Printed Name of Person Mailing Correspondence)</p><p> (Signature of Person Mailing Correspondence)</p><p><u>EL 408061868 US</u> ("Express Mail" Mailing Label Number)</p></div>			
<p>Note: Each paper must have its own certificate of mailing.</p>			



Patent
Our Docket: GAO118USC
Customer No. 24536


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Charles A. Nicolette)
Serial No.: 10/041,977)
Filed: January 9, 2002)
For: A METHOD FOR IDENTIFYING)
CYTOTOXIC T CELL EPITOPES)

Art Unit: 1627

Examiner:

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, Virginia 22202

CERTIFICATE OF MAILING BY EXPRESSMAIL
"EXPRESS MAIL" MAILING LABEL NO. EL 408061868 US
DATE OF DEPOSIT May 21, 2002
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS
BEING DEPOSITED WITH THE UNITED STATES
POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO
ADDRESSEE" SERVICE UNDER 37 CFR 1.10
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT
COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20530
Taryn Antalek
Name  Signature

STATEMENT UNDER 37 C.F.R. §1.821(e)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 22, 2002 in connection with the above-identified patent application and further in accordance with 37 C.F.R. §1.821(e), Applicant brings to the Office's attention related patent application, U.S. Serial No. 08/989,195, filed December 11, 1997, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Applicant respectfully requests that the Sequence Listing in computer readable form supplied in compliance with 37 C.F.R. § 1.821 in the above-referenced parent application, *i.e.*, U.S. Serial No. 08/989,195, be made of written record and used in the examination of the subject application.

I hereby state, as required by 37 C.F.R. §1.821(e), that the content of the paper copy of the Sequence Listing submitted herewith in connection with the subject

In re: Nicolette
USSN: 10/041,977
Filed: January 9, 2002
Page 2

application is identical to the computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR § 1.821 in parent application U.S. Serial No. 08/989,195, filed December 11, 1997, now U.S. Patent No. 6,338,945, issued January 15, 2002.

No fee is deemed necessary in connection with the filing of this Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

05/21/02
Date

Deborah A. Dugan
Deborah A. Dugan
Registration No. 37,315
Telephone: (508) 270-2598
Facsimile: (508) 872-5415

GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322



UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 21 2002

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/041,977	01/09/2002	Charles A. Nicolette	GA0118USC

CONFIRMATION NO. 7476

 24536
 GENZYME CORPORATION
 LEGAL DEPARTMENT
 15 PLEASANT ST CONNECTOR
 FRAMINGHAM, MA 01701-9322

FORMALITIES LETTER



OC000000007697699

Date Mailed: 03/22/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

06/05/2002 NPRASASD 00000003 071074 10041977

01 FC:105 130.00 CH



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE